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Introduction
In 2008 a paper published in the American Journal of Clinical Pathology1 reported that a new
Mycobacterium species had been isolated from two patients with diffuse lepromatous leprosy
(DLL). A subsequent paper2 elaborated on the initial data without adding additional cases.
In this editorial we review the clinical, pathological andmolecular biological findings reported
in these two papers and discuss whether there is sufficient evidence to support the claim of a
newMycobacterium species causing diffuse lepromatous leprosy.Diffuse lepromatous leprosy
manifests clinically with diffuse, non-nodular dermal infiltration3 and pathologically with
evidence of mycobacteria in the endothelium and lepromatous granulomatous vasculitis.4
The clinical data on the two cases is given in the first paper.Both patientswereMexicanswho
died in intensive care/burn facilities in Phoenix, Arizona, USA with extensive necrotising skin
lesions.Case 1 hadmultiple purpuric skin lesionswith necrosis and vasculitis present.Case 2 had
80% skin necrosis with multiple skin lesions. Biopsies from both lesions showed acid fast bacilli
in macrophages with vasculitis. The diagnoses in both cases were compatible with Lucio
reactions. DNA and bacteria were isolated from the frozen post-mortem liver of case 1 and the
stored paraffin embedded skin biopsy of case two and used for the subsequentmolecular studies.
Han et al.1 proposed the nameMycobacterium lepromatosis for the disease-causing agent
because of the close genetic relationship toM. leprae and the apparent association with DLL.
Using purified DNA, five genes (mmaA, hsp65, rpoT, rpoB and rif-rpoS) were partially
sequenced and one gene (rrs, 16S RNA) was fully sequenced. All sequences were compared
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with M. leprae consensus sequences and a few other mycobacteria to derive genetic
relationships. Based on these comparisons the authors argued that the genetic differences
were significant enough to propose a novel species. The second report2 is a more in-depth
genetic analysis of the DNA (FJ924) derived from one of the leprosy patients. In this study the
investigators analysed full and partial sequences of 20 genes and pseudogenes from the DNA,
surveying approximately 0·6% of the theoretical genome. They again concluded that
sequence data from FJ924 DNA substantiated the species-level difference with M. leprae.
Other phylogenetic results attempted to place the proposed new species and M. leprae in the
context of evolutionary distance from a common ancestor.
NEW MYCOBACTERIUM SPECIES?
Han et al.1,2 reported that genetic differences between FJ924 DNA and M. leprae are
significant enough to propose a novel species. While relatively large sequence differences
were reported for some conserved and many less conserved genes, the primary comparison is
with full length 16S RNA. This is appropriate because systematic comparisons of DNA
sequence are most robust and meaningful when using full-length genes for comparisons.5
The authors show that the 16S RNA from M. leprae and FJ924 both contain an AT-rich
region, not seen in other mycobacteria, and that the overall 16S RNA sequences are 98%
identical. While 2% divergence of 16S RNA sequence is not generally sufficient to support
species differentiation,5 this difference is particularly noteworthy when considering the large
number of reported M. leprae 16S RNA sequences (www.ncbi.nlm.nih.gov/genbank)
showing much less diversity. Taking the 16S RNA data along with some 20 other genes
that were partially sequenced, raises questions; have the investigators isolated a variant
of M. leprae that causes leprosy that is clinically indistinguishable from leprosy caused by
the type strain, M. leprae, or have the investigators isolated DNA from a bacterium very
closely related to M. leprae that was found associated with leprosy infections but not the
cause of the disease?
Infection with environmental mycobacteria in cutaneous lesions in leprosy patients,
have been reported6 and could explain the DNA identified by Han et al. Alternatively, the
suggestion that diffuse lepromatous leprosy is caused by a bacterium that is very closely
related to M. leprae but clearly different from the type strain requires further study to
authenticate this claim.
ESTABLISHING CAUSATION OF DISEASE
An important milestone in establishing the ‘Germ Theory’ in medicine was the
application of Henle’s postulates to establish the causal relationship between a microbe
and a disease. Henle’s work was later refined by his student Robert Koch, to become
known as Henle-Koch’s postulates. The postulates state that the following criteria have to
be met for an agent to be established as the cause of an infectious disease; (1) the agent
must be present in every case of disease (recognising asymptomatic carriers can exist),
(2) the agent must be isolated from lesions in pure culture, (3) the agent must be
inoculated into a susceptible host reproducing the disease and (4) the agent must be
recovered from the lesions.
With the leprosy bacillus the steps requiring growth of the agent have been impossible
to meet because the bacterium cannot be grown in culture. The same is apparently true of
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the agent FJ924 though only a few attempts at cultivation have been made. As a surrogate
for cultivation, DNA obtained from bacteria found in leprosy lesions have been repeatedly
shown to be essentially identical to the type strain of M. leprae.7,8 In addition, M. leprae has
been isolated from human lesions, passaged in mice and armadillos and recovered from
infected tissues. These passaged bacteria have been shown to cause characteristic
granulomatous lesions with nerve invasion in the armadillo, the hallmark of M. leprae
infection in man. Similar studies have not been forthcoming from Han’s group using the
agent FJ924. These kinds of studies are essential to establish the linkage between the suspect
agent from which DNA has been isolated from a small number of patients and the claim that
the causative agent is separate and distinct from M. leprae.9
CLINICO-PATHOLOGICAL FEATURES OF DLL
A century ago, leprologists were debating whether or not different organisms or strains
of M. leprae existed and caused the differing clinical and histological appearances of
the leprosy types in the Ridley-Jopling spectrum. They also asked whether different
organisms might cause the different leprosy ‘reactions’ in patients – ENL, RR, or Lucio’s.
All of these differences and complications have since been shown to be the result of
individual host responses to M. leprae antigens, with the possible exception of the Lucio
reaction, which consists of ischemic infarcts of the skin, the mechanism of which is still
very poorly understood. Thus, the possibility that a strain of M. leprae might encode
unique characteristics that could elicit the Lucio reaction is attractive and seems plausible,
although highly speculative and challenging to prove, since genetic clonality and
the absence of overt toxic affects in animal models seem to be major characteristics of
M. leprae.
The ‘new organism’ described in the initial report was obtained from lesions of two
patients with the Lucio reaction, but the authors then generalised beyond the Lucio
phenomenon and asserted that this new organism was responsible for diffuse lepromatous
leprosy (DLL). DLL is a clinical variant of lepromatous leprosy described by Latapi.10
In DLL diffuse infiltration of the skin is observed, without nodular lesions that occur in
lepromatous leprosy. Histological features of this variant overlap with those of more
common, nodular lesions, and DLL is usually diagnosed retrospectively in persons who
develop the Lucio Reaction.4 To associate a new strain or species of organism with this
clinical variant of LL seems highly premature with so few cases reported. Moreover, since the
different clinical manifestations of tuberculoid and lepromatous disease are elicited by one
organism, it seems unlikely that such a clinical variant of LL would be the result of a different
strain or species of organism.
The two cases underpinning this are both deceased and so it is very tenuous to ascribe
a specific clinical condition that was not recognised in life to a new Mycobacterium
species. It can be said that FJ924 is associated with two cases of Lucio’s phenomenon. It is
not possible to say that FJ924 caused the disease in these two cases. While it is
theoretically possible for different M. leprae strains to cause different disease types, so far
no evidence has been found to support this hypothesis and the pathological model in
which the immune response of the host is paramount in determining disease outcome still
holds good. There is solid evidence for minor DNA changes in M. leprae at the strain
level and these differences have been used for molecular epidemiological studies11 and
drug resistance.12
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EXPERIMENTS NEEDED TO VERIFY CLAIM OF NEW MYCOBACTERIUM SP CAUSES
LEPROSY
Whether Han et al. have isolated DNA from a new Mycobacterium species or a variant
of M. leprae, prospective studies must be performed to confirm the claim that this agent
causes leprosy. The work to attain this milestone is not trivial and will require the
collaboration of many clinical and research sites. First, bacteria from patients harbouring
the suspect agent will have to be isolated. Every attempt should be made to grow and
isolate the agent using culture with standard mycobacterial media. If this approach is
unsuccessful, mouse foot pads should be inoculated with biopsy material from patients
suspected of harbouring the agent so that ‘pure’ collections of the bacteria can be grown
and further analysed. Growth in the mouse foot pad assumes that the suspected agent
can replicate, as does M. leprae, in the foot pads of mice. Because this is uncertain,
multiple attempts will have to be carried out using different conditions to confirm absence
or presence of mycobacterial growth. If the bacteria can be passaged successfully in mice,
samples of infected tissues must be collected at each stage of passage to monitor
the genetic characteristics of the bacteria. The agent may be found in association with
M. leprae and passage in the mouse may be permissive for one bacterium over the other
causing potential changes in proportion of agents over time. Because of this potential
enrichment artifact, multiple, successful expansions of ‘M. lepromatosis’ in the mouse will
be needed.
Upon successful expansion and genetic characterisation showing ‘purity’ of the bacteria,
expansion in nude mice would help prepare large numbers of the bacteria needed for the
next phase of characterisation. Nude mouse-derived bacteria would be harvested and injected
into naı¨ve armadillos to monitor the bacteria’s ability to infect nerves, the hallmark pathology
associated with leprosy. Other than man, armadillos are the only known naturally susceptible
host for M. leprae and nerve infection is seen with all animals infected with M. leprae.11
Expansion of the infection in the armadillo with subsequent nerve invasion by the suspect
agent would confirm that the bacterium is capable of causing a leprosy-like infection. If nerve
invasion is not observed, the bacteria cannot be considered a new Mycobacterium species
causing leprosy.
SUMMARY
Han et al.1,2 have made a retrospective isolation of DNA from two patients with fatal Lucio’s
phenomenon. This DNA does have some molecular differences to M. leprae and may
constitute a variant of M. leprae. However the experiments and data needed to confirm
that this is a new leprosy-causing species have not yet been done. We have outlined the work
that does need to be done. For the moment the assertion that ‘M. lepromatosis’ is a new
leprosy-causing species is not proven.
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